TNGX (Tango Therapeutics) Total Stockholders Equity: $1,024.53 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TNGX Tango Therapeutics Inc TNGX
54 GF Score
Price $21.74
GF Value $9.80
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Tango Therapeutics Total Stockholders Equity?

Tango Therapeutics TNGX -7.41% 54 Total Stockholders Equity is $1,024.53 Mil as of Jun. 2026. GuruFocus rates TNGX with a GF Score™ of 54/100 and a GF Value™ of $9.80 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Tango Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $1,024.53 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Tango Therapeutics's Book Value per Share for the quarter that ended in Jun. 2026 was $6.08. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Tango Therapeutics's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.03.

Tango Therapeutics  (NAS:TNGX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Tango Therapeutics's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(1024.532-0)/168.380091
=6.08

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Tango Therapeutics's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(2.943 + 29.049) / 1024.532
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tango Therapeutics Total Stockholders Equity Related Terms

Tango Therapeutics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Tango Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tango Therapeutics Total Stockholders Equity Chart

Tango Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial 344.75 249.48 253.11 199.52 346.18

Tango Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 134.95 160.03 346.18 391.51 1,024.53
TNGX
54GF Score
Tango Therapeutics Inc TNGX
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $1,024.53 Mil mean?
Tango Therapeutics (TNGX) has a Total Stockholders Equity of $1,024.53 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Tango Therapeutics and its competitors.
Is Tango Therapeutics' Total Stockholders Equity too high?
Tango Therapeutics' current Total Stockholders Equity is $1,024.53 Mil. Overall, Tango Therapeutics has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tango Therapeutics' Total Stockholders Equity compare to IDYA and LEGN?
Tango Therapeutics' Total Stockholders Equity of $1,024.53 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Tango Therapeutics and its competitors. Tango Therapeutics's current Total Stockholders Equity is $1,024.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tango Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Tango Therapeutics (TNGX) is currently considered Significantly Overvalued. The stock's GF Value™ is $9.80, compared to a current price of $21.74 — trading 121.8% above its estimated fair value. The current Total Stockholders Equity is $1,024.53 Mil. Tango Therapeutics' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Tango Therapeutics (TNGX), the current Total Stockholders Equity is $1,024.53 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tango Therapeutics (TNGX) Overvalued in 2026?

Based on GuruFocus' analysis, Tango Therapeutics stock appears to be overvalued. The current stock price of $21.74 is trading 121.8% above its estimated GF Value™ of $9.80. GuruFocus considers Tango Therapeutics to be Significantly Overvalued.

Key valuation signals for TNGX:

  • Total Stockholders Equity: $1,024.53 Mil
  • GF Value™: $9.80 vs. price of $21.74 (121.8% above fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the TNGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tango Therapeutics Business Description

Address 201 Brookline Avenue, Suite 901, Boston, MA, USA, 02215
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
54GF Score

Get the complete analysis for TNGX

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.74
Price
$9.80
GF Value